618 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,428 published Semaglutide COA source records from third-party laboratories, covering 609 publicly attributable vendor identities. Across 2,222 records with positive numeric purity, the arithmetic mean is 99.66%. 12 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 3 positive purity results are below 90%; 90 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-20, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $5.50 | $5.50–$5.50 | $1.10 | 1 source · 1 offer |
| 10 mg | $8.00 | $8.00–$8.00 | $0.80 | 1 source · 1 offer |
| 15 mg | $9.50 | $9.00–$10.00 | $0.63 | 2 sources · 2 offers |
| 20 mg | $11.83 | $10.50–$13.00 | $0.59 | 3 sources · 3 offers |
| 30 mg | $16.00 | $14.00–$18.00 | $0.53 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-20T02:05:59.096029+00:00. Calculation time is not a laboratory observation date.
Within that total, 482 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 45 | 99.8% | 0 of 40 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 34 | 99.48% | 0 of 30 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 29 | 99.43% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120870 (99.76%) · #120569 (99.95%) · #120845 (99.8%) · #120837 (99.85%) · #120830 (99.79%) · #120620 (99.57%)
This case report suggests a rare but important potential side effect of **semaglutide** that clinicians and users should be aware of. **If experiencing unexplained symptoms like galactorrhea, menstrual irregularities,…
This study provides critical molecular insights into how **semaglutide** and **dapagliflozin** exert their kidney-protective effects in **Type 1 diabetes**, specifically within the S3 segment. The distinct and overlap…
**Semaglutide's potential as a dual-target therapy for MAALD could fundamentally reshape how this complex liver disease is managed**, offering a single, potent agent to address both the metabolic dysfunction and the i…
This **Phase 3 trial** is crucial for establishing the long-term cardiovascular safety and efficacy profile of **semaglutide** in **Type 2 Diabetes**. If successful, the findings could further solidify semaglutide's r…
**If NT-0796 proves safe and effective as a semaglutide adjunct, it could offer a significant advancement for individuals with obesity.** This combination therapy might lead to enhanced weight loss, improved metabolic…
If successful, this study could significantly advance the treatment landscape for **adolescent obesity**, providing a much-needed long-term pharmacological option. Current therapies often struggle with sustained effic…
A randomized, placebo-controlled clinical trial is evaluating **semaglutide**'s effect on early liver fibrosis and fat deposition in patients with nonalcoholic fatty liver disease.
Subcutaneous semaglutide will be assessed for safety and efficacy in a new trial targeting Systemic Sclerosis, exploring its potential beyond metabolic indications.
Review synthesizes evidence on *Akkermansia muciniphila*'s role in **Alzheimer's Disease** pathogenesis via the gut-brain axis, immune modulation, and barrier integrity.
**Targeting the redox–mitochondrial axis could offer novel strategies for combating obesity and metabolic disease.** By understanding how this axis drives beige fat immunometabolism and adipose inflammation, researche…
This case underscores the critical importance of **patient education and careful instruction** for individuals self-administering injectable medications like **semaglutide**, particularly when sourced from compounding…
**Cardiometabolic disease management must fundamentally shift from a glucose-centric focus to a comprehensive, organ-protective strategy.** This means clinicians and individuals at risk should consider **SGLT-2 inhibi…
**Semaglutide offers a promising adjunct therapy for selected individuals with Type 1 Diabetes**, potentially improving glycemic control and addressing weight management challenges often associated with insulin therap…
Ellagic acid was investigated for its hepatoprotective effects and modulation of `UPR-PERK` pathway mRNA expression in **metabolic dysfunction-associated fatty liver disease**.
An in vitro study evaluated a standardized phospholipid-formulated bergamot extract for its `GLP-1R`-associated activity, suggesting potential for metabolic health.
If successful, the COMBINE 2 trial could significantly **redefine the treatment paradigm for Type 2 Diabetes**. A once-weekly fixed-ratio combination of **insulin icodec** and **semaglutide** (IcoSema) could offer a p…
If **semaglutide** proves effective as an add-on to SGLT-2i, it could significantly **enhance glycemic control for patients with Type 2 Diabetes** who are not reaching their targets on SGLT-2i alone or in combination …
A study in healthy men compares the bioavailability of **semaglutide** from four different oral tablet formulations to identify optimal drug uptake.
This review underscores the growing importance of **GLP-1**-based medications as a potential cornerstone therapy for patients with **heart failure**, especially those with co-existing **type 2 diabetes** and **obesity…
This study highlights **ellagic acid as a potential complementary therapy for MAFLD**, offering a distinct mechanism of action by targeting the `UPR-PERK` pathway. For individuals managing metabolic dysfunction or MAF…
These findings underscore the complex, reciprocal relationship between insulin and incretin receptor agonists at the **blood-brain barrier**, highlighting potential implications for both therapeutic efficacy and neuro…
This research highlights a critical public health challenge: the growing influence of social media on the unsupervised use of prescription medications like **semaglutide**. For peptide users and biohackers, this under…
The advent of oral GLP-1 RAs represents a significant leap forward, potentially transforming the management of **obesity**, **metabolic syndrome**, and **type 2 diabetes**. **Oral formulations can dramatically improve…
**Accelerating the development and optimization of long-acting injectable (LAI) formulations** is a critical practical takeaway for peptide users and formulators. This interpretable machine learning framework signific…
This research provides a promising platform for overcoming major **GI tract barriers** to oral peptide delivery, potentially expanding the range of therapeutics that can be administered non-invasively. **Developing hi…
The expanding use of GLP-1RAs means clinicians and patients need a clearer understanding of their ocular safety and benefits. **Baseline ophthalmic assessment and individualized follow-up may be advisable for selected…
This meta-analysis provides compelling evidence that **semaglutide use is associated with an increased risk of NAION in T2DM patients, necessitating careful consideration in clinical practice.** For peptide users and …
This review highlights **semaglutide's potential as a novel therapeutic strategy for drug-induced liver injury (DILI)**, a condition with limited treatment options. For clinicians and biohackers, this suggests a broad…
This real-world evidence provides crucial insights for the off-label use of semaglutide in **Type 1 Diabetes**, suggesting it can improve glycemic control without increasing the risk of severe hypoglycemia or DKA hosp…
Semaglutide reduced weight gain in atherosclerotic ApoE-/- mice and is proposed to mitigate inflammation and endothelial dysfunction via the `Sema3A/NRP1` pathway.
This research highlights a novel, bone-protective mechanism for **Semaglutide** beyond its established glycemic control, suggesting its potential as a therapeutic agent for **diabetic periodontitis**. For individuals …
This network meta-analysis suggests that next-generation amylin-based therapies could offer significantly greater weight loss than current GLP-1RAs, potentially redefining obesity treatment paradigms. **Individuals se…
A 6-week randomized trial investigated continuous native **GIP** infusion, alone or with **semaglutide**, for glycemic control in **type 2 diabetes**. **61** participants were enrolled.
Semaglutide drives weight loss by activating Gs- and Gq-dependent signaling in hindbrain `GLP1R` neurons, with `cAMP` increases via `Gs` being critical. Disrupting these pathways abolishes semaglutide's weight loss.
This study provides compelling evidence that **semaglutide 2.4 mg weekly is a safe and effective treatment option for individuals experiencing suboptimal weight loss after bariatric surgery**. For peptide users and cl…
Commentary argues **semaglutide**'s stage-dependent effects on feeding and energy expenditure were interpreted via indirect proxies, requiring more direct mechanistic validation.
**Semaglutide's renal and cardiovascular protective effects are robust and extend to patients already receiving MRAs for CKD.** This reinforces confidence in combining **semaglutide** with existing standard-of-care th…
Combining semaglutide and canagliflozin offers a potent strategy for managing early diabetic kidney disease, potentially slowing its progression more effectively than either drug alone. For individuals with T2DM and e…
This review solidifies the expanding role of GLP-1-based therapies in metabolic liver disease, offering a promising avenue for patients with MASLD and MASH. For clinicians and biohackers, this reinforces the potential…
A clinical study is underway to assess how CagriSema, cagrilintide, and semaglutide impact muscle health in overweight individuals with prediabetes during weight loss.
The outcome of this trial could significantly impact the treatment landscape for Type 2 Diabetes. If flexible-dose oral semaglutide demonstrates superior efficacy or a comparable safety profile to sitagliptin, it coul…
Observational study explores if personality attributes and behavioral AI can predict patient adherence and weight loss success during a semaglutide program in the Latino community.
Semaglutide trial will assess its impact on circulating vessel-repairing cells over 6 months in patients with type 2 diabetes or obesity.
If this trial demonstrates a protective effect, it would represent a significant paradigm shift in managing diabetic eye disease. Semaglutide could become a crucial therapeutic option not just for glycemic control, bu…
This preclinical study highlights the promising potential of Cissus quadrangularis and Dichrostachys glomerata extracts as natural agents for obesity and metabolic health management. For biohackers and individuals exp…
Understanding the real-world benefits of switching from DPP-4i to oral semaglutide is critical for clinicians and patients managing T2DM. This study will provide valuable insights into how oral semaglutide performs in…
This review significantly expands the understanding of GLP-1 RAs beyond diabetes and obesity, establishing their utility in heart failure management, particularly for HFpEF/HFmrEF. For clinicians and biohackers, this …
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This study suggests that semaglutide could become a valuable adjunctive neuroprotective therapy for patients experiencing acute large vessel occlusion stroke, particularly those ineligible for or not receiving intrave…
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account